Risk stratification in nonmuscle-invasive bladder cancer (CME)

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

The accuracy of PLND was 93.41% in the ICG injection arm compared with 75.91% in the control arm.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring the evolving treatment landscape. Kamat is an endowed professor of urologic oncology and cancer research at the University of Texas MD Anderson Cancer Center and president of the IBCG (International Bladder Cancer Group) and former president of the IBCN (International Bladder Cancer Network). Dr. Kamat has been compensated by J&J for his time to develop this content.

Functional success was achieved in 58% of patients at 5-year follow-up.